article thumbnail

NYU’s Groundbreaking CBD/Epilepsy Study, WA’s Mushroom Legalization in Peril, & MD Pushes for Social Equity

Veriheal

An NYU study found that CBD could help those with epilepsy, Washington’s mushroom legalization bill hit a major roadblock, and Maryland is looking to include social equity in its forthcoming recreational market. This new CBD-epilepsy study comes from NYU’s Grossman School of Medicine. Let us know in the comments!

Epilepsy 104
article thumbnail

Nonprofits Team Up in the Battle Against Epilepsy in Children

Medical Marijuana Program Connection

–(BUSINESS WIRE)–Beginning in January 2024, natural medicine research nonprofits Realm of Caring, Unlimited Sciences and Lily’s Lighthouse will collaborate to collect data for an observational study on the efficacy of functional mushrooms in treating epilepsy. COLORADO SPRINGS, Colo.–(BUSINESS

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Epidiolex CBD Epilepsy Drug Receives Approval in Europe

WeedAdvisor

GW Pharmaceuticals created the medication after studies showed surprising success treating severe childhood epilepsy, specifically Lennox-Gastaut Syndrome and Dravet Syndrome. Now, Marijuana Business Daily reports that the European Commission has just approved the drug as well. In the U.S., Epidiolex costs $32,000 USD per year.

article thumbnail

Three Major Australian Medical Cannabis Companies Fined By The TGA “over claims prescriptions could treat conditions such as cancer and epilepsy”

Cannabis Law Report

Australia’s drugs regulator issues 73 infringement notices over claims prescriptions could treat conditions such as cancer and epilepsy. It is also alleged that the unlawful advertising included unapproved references to the treatment of serious diseases or conditions, including in some cases cancer and epilepsy.

article thumbnail

Global Epilepsy Pipeline Landscape Report 2021: Comprehensive Insights for 70+ Companies and 70+ Pipeline Drugs – ResearchAndMarkets.com

Cannabis Law Report

DUBLIN–(BUSINESS WIRE)–The “Epilepsy – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This Epilepsy – Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Epilepsy pipeline landscape.

article thumbnail

Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting

Cannabis Law Report

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Phase 2, Placebo-Controlled Clinical Study of Oral Ganaxolone in PCDH19-Clustering Epilepsy (the Violet Study). Marinus investor event: Marinus Pharmaceutical Virtual Investor Event at American Epilepsy Society 2021 Annual Meeting.

article thumbnail

Virpax to Develop Intranasal Cannabidiol Product for the Management of Epilepsy in Adults and Children

Cannabis Law Report

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. Nanomerics”) to use Nanomeric’s molecular envelope platform technology (MET) for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children.